Planegg, Bayern, Germany | Fund Name | Location |
| Anonymous Trust | California, San Francisco, United States |
| Asia Capital | Colombo, Sri Lanka, Western Province |
| Capital Fund Management | France, Ile-de-France, Paris |
| Corundum Open Innovations | Herzliya, Israel, Tel Aviv |
| Country Garden | China, Foshan, Guangdong |
| Dingqing Investment | Beijing, Beijing, China |
| Grit Ventures | California, Menlo Park, United States |
| Guangzhoushi Guoying Touzi Youxian Gongsi | China, Guangdong, Guangzhou |
| Kyodo News Digital | Chiba Prefecture, Japan, Tateyama |
| Luxmi Ventures | - |
| Maersk Line | Copenhagen, Denmark, Hovedstaden |
| Pall | New York, Port Washington, United States |
| Rosario Capital LTD | Israel, Tel Aviv, Tel Aviv District |
| Royal Majestics | Finland, Helsinki, Southern Finland |
| Rubicon Venture Capital | California, San Francisco, United States |
| The Optimas Group | Nebraska, Omaha, United States |
| Ventura Capital | Dubai, United Arab Emirates |
| Vivo Capital | California, Palo Alto, United States |
| Xin Chang Electronics Technology | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Human Immunology Biosciences | $120M | 01 Nov 2022 | San Francisco, California, United States | ||
Adivo | 20 Aug 2018 | Germany, Bavaria, Germany |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Human Immunology Biosciences | $120M | 01 Nov 2022 | San Francisco, California, United States | ||
Adivo | 20 Aug 2018 | Germany, Bavaria, Germany |
